Contemporary imaging analyses of pelvic lymph nodes in the prostate cancer patient

Current Opinion in Urology

Volumn 21, Issue 3, 2011, Pages 211-218

  Mattei, Agostino ^a   Danuser, Hansjörg ^a  

^a LUZERNER KANTONSSPITAL   (Switzerland)

Author keywords

imaging; lymph nodes; prostate cancer; staging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; IMAGE ANALYSIS; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 79955060817     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3283449428     Document Type: Article

References (51)

1. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008; 53:68-80. (Pubitemid 350166735)
2. Masterson TA, Bianco FJ Jr, Vickers AJ, et al. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 2006; 175:1320-1324.
3. Joslyn SA, Konety BR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006; 68:121-125. (Pubitemid 44037727)
4. DiMarco DS, Zincke H, Sebo TJ, et al. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 2005; 173:1121-1125. (Pubitemid 40380516)
5. Cuneo B, Marcille M. Topographie des ganglions-ilio-pelviens. Bull Mem Soc Anat Paris 1901; 6. ser.jt.III:653-663.
6. Flocks RH, Culp D, Porto R. Lymphatic spread from prostatic cancer. J Urol 1959; 81:194-196.
7. Gervasi LA, Mata J, Easley JD, et al. Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 1989; 142 (2 Pt 1):332-336. (Pubitemid 19197108)
8. McSherry SA, Levy F, Schiebler ML, et al. Preoperative prediction of pathological tumor volume and stage in clinically localized prostate cancer: comparison of digital rectal examination, transrectal ultrasonography and magnetic resonance imaging. J Urol 1991; 146:85-89
9. Jager GJ, Barentsz JO, Oosterhof GO, et al. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. AJR Am J Roentgenol 1996; 167:1503-1507. (Pubitemid 26418741)
10. Engeler CE, Wasserman NF, Zhang G. Preoperative assessment of prostatic carcinoma by computerized tomography. Weaknesses and new perspectives. Urology 1992; 40:346-350.
11. Perrotti M, Kaufman RP Jr, Jennings TA, et al. Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate? J Urol 1996; 156:106-109. (Pubitemid 26185650)
12. Hövels AM, Heesakkers RA, Adang EM. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008; 63:387-395.
13. Saokar A, Islam T, Jantsch M, et al. Detection of lymph nodes in pelvic malignancies with Computed Tomography andMagnetic Resonance Imaging. Clin Imaging 2010; 34:361-366.
14. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002; 167:1681-1686. (Pubitemid 34240702)
15. Bader P, Burkhard FC, Markwalder R. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002; 168:514- 518; discussion 518.
16. Wawroschek F, Vogt H, Wengenmair H. Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases. Urol Int 2003; 70:303-310. (Pubitemid 36566262)
17. Holl G, Dorn R, Wengenmair H, et al. Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2000 patients. Eur J Nucl Med Mol Imaging 2009; 36:1377-1382.
18. Jansen L, Nieweg OE, Kapteijn AE. Reliability of lymphoscintigraphy in indicating the number of sentinel nodes in melanoma patients. Ann Surg Oncol 2000; 7:624-630.
19. Takashima H, Egawa M, Imao T, et al. Validity of sentinel lymph node concept for patients with prostate cancer. J Urol 2004; 171 (6 Pt 1):2268-2271. (Pubitemid 38625449)
20. Weckermann D, Dorn R, Trefz M, et al. Sentinel lymph node dissection for prostate cancer: experience with more than 1000 patients. J Urol 2007; 177:916-920. (Pubitemid 46216337)
21. Warncke SH, Mattei A, Fuechsel FG, et al. Detection rate and operating time required for gamma probe-guided sentinel lymph node resection after injection of technetium-99m nanocolloid into the prostate with and without preoperative imaging. Eur Urol 2007; 52:126-132.
22. Mattei A, Fuechsel FG, Bhatta Dhar N, et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 2008; 53:118-125. (Pubitemid 350166722)
23. Ganswindt U, Schilling D, Müller AC, et al. Distribution of prostate sentinel nodes: a SPECT-derived anatomic atlas. Int J Radiat Oncol Biol Phys 2010. [Epub ahead of print]
24. Weckermann D, Dorn R, Holl G, et al. Limitations of radioguided surgery in high-risk prostate cancer. Eur Urol 2007; 51:1549-1556; discussion 1556-1558.
25. Schilling D, Boekeler U, Gakis G, et al. Modified concept for radioisotopeguided sentinel lymph node dissection in prostate cancer. World J Urol 2010; 28:715-720.
26. Jeschke S, Beri A, Grüll M, et al. Laparoscopic radioisotope-guided sentinel lymph node dissection in staging of prostate cancer. Eur Urol 2008; 53:126-132.
27. Vermeeren L, Muller SH, Meinhardt W, et al. Optimizing the colloid particle concentration for improved preoperative and intraoperative image-guided detection of sentinel nodes in prostate cancer. Eur J Nucl Med Mol Imaging 2010; 37:1328-1334.
28. Vermeeren L, Valdés Olmos RA, Meinhardt W, et al. Value of SPECT/CT for detection and anatomic localization of sentinel lymph nodes before laparoscopic sentinel node lymphadenectomy in prostate carcinoma. J Nucl Med 2009; 50:865-870.
29. Vermeeren L, Meinhardt W, Valdes Olmos RA. Prostatic lymphatic drainage with sentinel nodes at the ventral abdominal wall visualized with SPECT/CT: a case series. Clin Nucl Med 2010; 35:71-73.
30. Will O, Purkayastha S, Chan C, et al. Diagnostic precision of nanoparticleenhanced MRI for lymph-node metastases: a meta-analysis. Lancet Oncol 2006; 7:52-60. (Pubitemid 43025393)
31. Bellin MF, Roy C, Kinkel K, et al. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles: initial clinical experience. Radiology 1998; 207:799-808. (Pubitemid 28279916)
32. Bellin MF, Lebleu L, Meric JB. Evaluation of retroperitoneal and pelvic lymph node metastases with MRI and MR lymphangiography. Abdom Imaging 2003; 28:155-163. (Pubitemid 36459320)
33. Deserno WM, Harisinghani MG, Taupitz M, et al. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology 2004; 233:449-456. (Pubitemid 39423804)
34. Rockall AG, Sohaib SA, Harisinghani MG, et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 2005; 23:2813-2821. (Pubitemid 46179472)
35. Ross RW, Zietman AL, Xie W, et al. Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin Imaging 2009; 33:301-305.
36. Heesakkers RA, Jager GJ, Hövels AM, et al. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10- enhanced MR imaging. Radiology 2009; 251:408-414.
37. Dinniwell R, Chan P, Czarnota G, et al. Pelvic lymph node topography for radiotherapy treatment planning from ferumoxtran-10 contrast-enhanced magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2009; 74:844-851.
38. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348:2491-2499. (Pubitemid 36706536)
39. Heesakkers RA, Hövels AM, Jager GJ, et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008; 9:850-856.
40. Hövels AM, Heesakkers RA, Adang EM, et al. Cost-analysis of staging methods for lymph nodes in patients with prostate cancer: MRI with a lymph node-specific contrast agent compared to pelvic lymph node dissection or CT. Eur Radiol 2004; 14:1707-1712. (Pubitemid 39232905)
41. Hövels AM, Heesakkers RA, Adang EM, et al. Cost-effectiveness of MR lymphography for the detection of lymph node metastases in patients with prostate cancer. Radiology 2009; 252:729-736.
42. Meng MV, Carroll PR. When is pelvic lymph node dissection necessary before radical prostatectomy? A decision analysis. J Urol 2000; 164:1235-1240.
43. El-Galley RE, Keane TE, Petros JA, et al. Evaluation of staging lymphadenectomy in prostate cancer. Urology 1998; 52:663-667. (Pubitemid 28440177)
44. Cagiannos I, Karakiewicz P, Eastham JA, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003; 170:1798-1803. (Pubitemid 37254931)
45. Briganti A, Chun FK, Salonia A, et al. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur Urol 2007; 51:112-119.
46. King AD, Ahuja AT, Yeung DK, et al. Malignant cervical lymphadenopathy: diagnostic accuracy of diffusion-weighted MR imaging. Radiology 2007; 245:806-813. (Pubitemid 350127351)
47. Kim JK, Kim KA, Park BW, et al. Feasibility of diffusion-weighted imaging in the differentiation of metastatic from nonmetastatic lymph nodes: early experience. J Magn Reson Imaging 2008; 28:714-719.
48. Petralia G, Thoeny HC. DW-MRI of the urogenital tract: applications in oncology. Cancer Imaging 2010; 10:S112-S123.
49. Beer AJ, Eiber M, Souvatzoglou M, et al. Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)Ccholine PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer. Mol Imaging Biol 2010. [Epub ahead of print]
50. Eiber M, Beer AJ, Holzapfel K, et al. Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol 2010; 45:15-23.
51. Thoeny HC, Triantafyllou M, Birkhaeuser FD, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion- weightedmagnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 2009; 55:761-769